AbbVie takes $216M charge on Q3 deals, cuts earnings

The charge moved the needle on full-year guidance. AbbVie's adjusted diluted EPS range for 2026 is now $13.76 to $13.96, down from the prior range of $13.87 to $14.07 announced July 31. For Q3 alone, the company guided to $3.73 to $3.77 per share, versus $3.84 to $3.88 before the charge.

AbbVie does not forecast acquired IPR&D and milestones expenses because licensing deals and asset purchases close unpredictably. The company excluded this category from its prior guidance, then disclosed the Q3 hit when results came in. The filing notes that results for the quarter ended September 30 have not been finalized and remain subject to closing procedures.

The $216 million figure represents what AbbVie paid for one or more licenses, partnerships, or assets it acquired during the quarter. The document does not specify which deals drove the charge or name any counterparties. AbbVie's Allergan Aesthetics unit operates within the broader company, but the 8-K does not break out whether the charge relates to aesthetics, other therapeutic areas, or a mix.

What the filing says about the charge

Item 2.02 of the 8-K, titled "Results of Operations and Financial Condition," states that acquired IPR&D and milestones expense may arise when AbbVie executes licenses, partnerships, and other asset purchases. The company treats these as one-time events tied to deal closure, not recurring operational costs. Because AbbVie cannot reliably forecast when or whether such deals will occur, it does not include them in forward guidance until they close.

The $216 million pre-tax hit to Q3 results forced AbbVie to restate its full-year 2026 adjusted diluted EPS guidance. The prior range of $13.87 to $14.07 excluded any acquired IPR&D and milestones expense beyond the second quarter. The new range of $13.76 to $13.96 incorporates the Q3 charge but still excludes any similar expense that may occur in Q4, since those deals cannot be reliably forecasted.

What remains uncertain

The filing does not disclose the nature, size, or therapeutic area of the underlying deals. It does not name any acquired companies, licensed assets, or partners. The 8-K states only that results for the quarter ended September 30 have not been finalized and are subject to financial statement closing procedures, leaving open the possibility that the $216 million figure could change before the company files its full quarterly report.

AbbVie's forward-looking statements section notes that the company faces risks including challenges to intellectual property, competition from other products, difficulties in research and development, adverse litigation or government action, and changes to laws and regulations. It also cites global macroeconomic factors such as economic downturns, international conflict, trade disputes, and tariffs as potential sources of uncertainty.

The filing is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act, meaning it does not carry the same legal liability as a formal quarterly or annual report. AbbVie will not revise forward-looking statements as a result of subsequent events or changes, except as required by law.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.